advertisement
Abstract #17601 Published in IGR 9-2
Experimental study of TGF-β(2) antisense oligodeoxynucleotide as an anti-scarring agent in glaucoma surgery
Li J-Y; Fu P; Yang QInternational Journal of Ophthalmology 2007; 7: 10-14
AIM: Currently available anti-scarring regimens for glaucoma filtration surgery have potentially blinding complications and safer alternatives would be beneficial. This experiment is to investigate the effect of TGF-β(2) antisense oligodeoxynucleotide on differentiation, proliferation of subconjunctival fibroblast following glaucoma filtration surgery. METHODS: Glaucoma filtration surgery were performed on both eyes of 28 rabbits. TGF-β(2) antisense oligodeoxynucleotide was subconjunctivally injected in the right eyes (A group), and TIF-β(2) missense oligodeoxynucleotide (B group) or PBS(C group) was used at the same method in the left eyes as controls. Rabbits were killed at 4,7,14 and 28 days after surgery. Intraocular pressure (IOP), bleb characteristics were recorded at different time point. Subconjunctival fibroblasts were examined by immunohistochemistry and electron microscopy. RESULTS: The IOP of rabbits in group A was significantly lower at 14 days (6.74 ± 1.18 mmHg) and 21 days (8.15 ± 1.97 mmHg) after operation than the IOP in group B (8.53± 1.04, 9.72 ± 1.09 mmHg)(P < 0.01) and group C (8.79 ± 1.21, 9.43 ± 1.27 mmHg) (P < 0.05). The mean bleb survival time was longer (17.2 days) in group A than that of group B (14.5 days) and group C (13.5 days) (P < 0.05). The population of the cells expressing α-smooth muscle actin(α-SMA) and proliferating cell nuclear antigen (PCNA) was significantly reduced in group A compared with the group B and C. The ultrastructure of fibroblast was not altered by TGF-β(2) anti-sense oligodeoxynudeotide. CONCLUSION: TGF-β(2) antisense oligodeoxynucleotide can prevent the scar formation after glaucoma surgery by inhibit the differentiation and proliferation of subconjunctival fibroblast. It could be a potentially useful anti-scarring alternative for the prevention of late surgical failure.
Dr. J.-Y. Li, Department of Ophthalmology, Peking University, Shenzhen Hospital, Shenzhen 518036 Guangdong Province, China. ljy19692004@yahoo.com.cn
Classification:
12.8.10 Woundhealing antifibrosis (Part of: 12 Surgical treatment > 12.8 Filtering surgery)
11.14 Investigational drugs; pharmacological experiments (Part of: 11 Medical treatment)